Active, not recruitingPhase 2NCT04595747
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Studying Gastrointestinal stromal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Suzanne George, MDDana-Farber - Harvard Cancer Center LAO
- Intervention
- Biopsy Procedure(procedure)
- Enrollment
- 48 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (18)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- City of Hope at Irvine Lennar, Irvine, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
- Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Siteman Cancer Center-South County, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04595747 on ClinicalTrials.govOther trials for Gastrointestinal stromal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego
- RECRUITINGNANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPHASE1NCT06655246A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Kura Oncology, Inc.
- RECRUITINGNANCT06926374Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic SurgeryChinese University of Hong Kong
- RECRUITINGNANCT07411118RCT of EFTR Versus STER for GIST TreatmentChinese University of Hong Kong
- RECRUITINGPHASE1, PHASE2NCT06630234A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)Deciphera Pharmaceuticals, LLC
- RECRUITINGPHASE3NCT06640361A Study of Olverembatinib in SDH-deficient GIST.Ascentage Pharma Group Inc.